NON-INTERVENTIONAL REAL-WORLD EUROPEAN STUDY QUANTIFYING THE BURDEN OF CENTRAL NERVOUS SYSTEM (CNS) METASTASES ON HEALTHCARE RESOURCE USE (HRU) IN PATIENTS WITH METASTATIC NON-SMALL-CELL LUNG CANCER (MNSCLC) – RESULTS FROM AN INTERIM ANALYS ...

Author(s)

Crane G¹, Khan N², Pedrós M³, Hipp J⁴, Gally S⁵, Smoljanovic V⁶, Gondos A⁷, Hammerschmidt S⁸
¹Roche (RWD), Welwyn Garden City, UK, ²QuintilesIMS, Mendham, NJ, USA, ³QuintilesIMS, Barcelona, Spain, ⁴Roche Pharma AG, Grenzach-Wyhlen, Germany, ⁵Roche SAS, Boulogne-Billancourt, France, ⁶F. Hoffmann-La Roche Ltd., Basel, Switzerland, ⁷QuintilesIMS, Frankfurt, Germany, ⁸Klinikum Chemnitz gGMBH, Chemnitz, Germany

Presentation Documents

PRM159--strong-u-crane-g-u-sup-1-sup-strong-khan-n-sup-2-sup-pedros-m-sup-3-sup-hipp-j-sup-4-sup-gally-s-sup-5-sup-smoljanovic-v-sup-6-sup-gondos-a-sup-7-sup-hammerschmidt-s-sup-8-sup-br-sup-1-sup-roche-rwd-welwyn-garden-city-uk-sup-2-sup-q ...

OBJECTIVES: Limited information is available regarding CNS metastases impact on HRU and HRQoL for patients with mNSCLC in Europe. This ongoing study (MO39084) compares HRQoL and HRU in mNSCLC patients with and without CNS metastases alongside demographic/clinical characteristics and concomitant medications.

METHODS: Patients ≥≥HRU data are collected via validated patient questionnaires and clinical charts

RESULTS: At data cut-off (29 May 2017), 123 patients were eligible: CNS metastases cohort n=49 and non-CNS metastases cohort n=74. Baseline characteristics were similar between cohorts: mean age 63 vs 67 years; 53% vs 66% male; mean BMI 23.6 vs 24.9 kg/m; ex-smoker status 51% vs 47%; mean time since diagnosis 6.1 vs 5.4 months; ECOG PS 1 55% vs 54%, and 1-2 chronic comorbidities 51% vs 49%. At V1, 41% (CNS metastases cohort) and 14% (non-CNS metastases cohort) had ≥3 metastatic sites (p=0.002). Dyspnoea (16% vs 31%, p=0.07), cough (14% vs 28%, p=0.07) and pain (12% vs 28%, p=0.03) were more common in the non-CNS metastases cohort. Similar HRU patterns were recorded in the cohorts before V1; no significant differences in number of hospitalizations (p=0.75), emergency room (p=0.22) or outpatient visits (p=0.22). Length of hospital stay was significantly longer in the CNS metastases cohort (p<0.001).

CONCLUSIONS: Interim data from a small sample suggest that the CNS and non-CNS metastases cohorts have similar HRU, except length of hospital stay. Final analyses including the full patient cohort will help understand the economic impact of this difference.

Conference/Value in Health Info

2017-11, ISPOR Europe 2017, Glasgow, Scotland

Value in Health, Vol. 20, No. 9 (October 2017)

Code

PRM159

Topic

Methodological & Statistical Research

Topic Subcategory

PRO & Related Methods

Disease

Oncology

Explore Related HEOR by Topic

Methodology

Presentation